KR20140071716A - Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent - Google Patents
Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent Download PDFInfo
- Publication number
- KR20140071716A KR20140071716A KR1020120139605A KR20120139605A KR20140071716A KR 20140071716 A KR20140071716 A KR 20140071716A KR 1020120139605 A KR1020120139605 A KR 1020120139605A KR 20120139605 A KR20120139605 A KR 20120139605A KR 20140071716 A KR20140071716 A KR 20140071716A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cosmetic composition
- effect
- present
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 239000000284 extract Substances 0.000 title claims abstract description 96
- 239000002537 cosmetic Substances 0.000 title claims abstract description 80
- 239000004480 active ingredient Substances 0.000 title claims abstract description 11
- 240000008027 Akebia quinata Species 0.000 title abstract description 5
- 235000007756 Akebia quinata Nutrition 0.000 title abstract description 5
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 20
- 230000003405 preventing effect Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000052 vinegar Substances 0.000 claims description 17
- 235000021419 vinegar Nutrition 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 230000002335 preservative effect Effects 0.000 claims description 12
- 230000037303 wrinkles Effects 0.000 claims description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 5
- 230000002087 whitening effect Effects 0.000 claims description 5
- 240000006439 Aspergillus oryzae Species 0.000 claims description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 230000009759 skin aging Effects 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 33
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract description 16
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract description 16
- 239000000463 material Substances 0.000 abstract description 5
- 230000036570 collagen biosynthesis Effects 0.000 abstract description 3
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 57
- 238000004519 manufacturing process Methods 0.000 description 41
- 230000000052 comparative effect Effects 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 25
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 14
- 102000008186 Collagen Human genes 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- 239000001569 carbon dioxide Substances 0.000 description 11
- 229910002092 carbon dioxide Inorganic materials 0.000 description 11
- 239000006071 cream Substances 0.000 description 11
- -1 for example Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008099 melanin synthesis Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 240000005125 Myrtus communis Species 0.000 description 6
- 235000013418 Myrtus communis Nutrition 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000002780 melanosome Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241000220284 Crassulaceae Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000237501 Crassostrea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 241000228153 Penicillium citrinum Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- OTQIFVPQYATWAJ-UHFFFAOYSA-N ethyl n-imidazolidin-1-ylcarbamate Chemical compound CCOC(=O)NN1CCNC1 OTQIFVPQYATWAJ-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 으름덩굴 추출물을 유효 성분으로 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition comprising an extract of Aspergillus as an active ingredient.
사람의 피부는 노화 과정에서 다양한 물리화학적인 변화가 일어난다. 그 원인으로는 크게 내적인 노화 (intrinsic aging)와 광노화 (photo-aging)로 구분되며 이에 관한 연구가 활발히 이루어져 왔다. 자외선, 스트레스, 질병 상태, 환경 인자, 상처, 나이가 들어감에 따라 자유라디칼이 활성화되어 야기될 수 있으며, 이런 상태가 심화될 경우 생체 내에 존재하는 항산화 방어망을 파괴하고, 세포 및 조직을 손상시켜 성인병 및 노화를 촉진하게 된다. In human skin, various physical and chemical changes occur in the aging process. The cause of this phenomenon is divided into intrinsic aging and photo-aging. Free radicals can be caused by activation of ultraviolet rays, stress, disease state, environmental factors, wounds, and aging. When such state is deepened, the antioxidant defense network existing in the living body is destroyed, And aging.
좀 더 구체적으로 말하자면, 피부의 주요 구성 물질인 지질, 단백질, 다당류 및 핵산 등이 산화되어 피부 세포 및 조직이 파괴되고, 결국 피부 노화 현상이 생겨나는 것이다. More specifically, lipids, proteins, polysaccharides and nucleic acids, which are major components of the skin, are oxidized to destroy skin cells and tissues, resulting in skin aging.
특히, 단백질의 산화는 피부의 결합 조직인 콜라겐 (collagen), 히아루론산 (hyaluronic acid), 엘라스틴 (elastin), 프로테오글리칸 (proteoglycan), 피브로넥틴 (fibronectin) 등이 절단되어 심한 과다 염증 반응과 피부의 탄력에 지장을 주고 이것이 더 심해질 경우 DNA의 변이에 의해 돌연변이, 암의 유발, 면역 기능 저하의 사태에 이르게 된다.In particular, the oxidation of proteins can cause collagen (collagen), hyaluronic acid, elastin, proteoglycan, fibronectin, and the like that are severely hyperinflammatory reactions and skin elasticity If this gets worse, DNA mutations can lead to mutations, cancer, and immune deficiency.
그러므로, 신체의 대사 과정 중 발생하는 자유라디칼이나 자외선 조사, 염증 반응에 의해 매개되어 발생하는 자유라디칼을 소거하여 세포막을 보호하고, 또 이미 손상 받은 세포는 활발한 신진 대사에 의해 재생시켜서 세포를 증식시켜야 피부는 빠르게 회복되고 건강한 피부를 유지할 수 있다. Therefore, it is necessary to protect the cell membrane by destroying the free radicals mediated by free radicals, ultraviolet rays, and inflammation that occur during the metabolism of the body, and to regenerate already damaged cells by vigorous metabolism The skin can quickly recover and maintain healthy skin.
노화에는 이러한 자유라디칼 뿐만 아니라 콜라겐 분해효소인 기질 금속 단백질 분해 효소 (Matrix Metalloproteinase; MMP)라는 효소도 관여한다. 즉, 생체 내에서 콜라겐과 같은 세포외기질의 합성과 분해는 적절하게 조절되나, 노화가 진행되면서 콜라겐 합성이 감소하고, 콜라겐을 분해하는 효소인 기질 금속 단백질 분해 효소(MMP)의 발현이 촉진되어 피부의 탄력이 저하되고 주름이 형성된다. 또한, 자외선 조사에 의해 이러한 분해 효소가 활성화되기도 한다. Aging involves not only these free radicals, but also enzyme called matrix metalloproteinase (MMP), a collagenase. That is, synthesis and degradation of extracellular matrix such as collagen in vivo are appropriately controlled, but collagen synthesis is reduced as aging progresses, and expression of matrix metalloproteinase (MMP), an enzyme that degrades collagen, is promoted, And the wrinkles are formed. These degrading enzymes are also activated by ultraviolet irradiation.
그러므로, 세포 내에서 활성화가 유도되는 MMP 발현을 조절하거나 그 활성을 억제할 수 있는 물질의 개발이 요구되고 있다. 이제까지 화장품의 소재로서 사용된 원료들은 단순히 효소 활성만을 억제하는 것이 대부분이었다. 이에 세포내 자연노화와 광노화에 의해 그 발현이 유도되는 MMP 발현량 및 활성을 조절하고자 하였다.Therefore, there is a demand for development of a substance capable of modulating MMP expression induced in the cell or inhibiting its activity. Until now, the raw materials used as cosmetic materials mostly inhibited only the enzyme activity. Therefore, we tried to control the amount and activity of MMP expression induced by intracellular natural aging and photoaging.
한편, 색소 침착에 의한 피부 변화가 생긴다. 피부색을 결정하는 인자에는 기본적으로 인종과 지역, 성별, 나이에 따른 차이를 배제하면 기미, 주근깨와 자외선 노출로 인한 태닝과 같은, 부분 또는 전체적인 색소 침착, 그 외에 여드름 및 흉터, 각질의 분포 상태와 혈액 순환, 스트레스, 건강 상태 등이 있다. 이상의 인자들 가운데에서도 가장 중요한 인자는 색소 침착이다.On the other hand, skin changes due to pigment deposition occur. The factors that determine skin color are basically the partial or total pigmentation such as stain, freckle and tanning due to ultraviolet exposure, and the distribution of acne and scars and keratin Blood circulation, stress, and health. The most important factor among these factors is pigmentation.
피부색에 영향을 주는 색소로는 멜라닌, 멜라노이드, 카로틴, 헤모글로빈 등이 있는데, 이중 가장 중요한 것은 멜라닌으로서, 이 멜라닌의 생합성에 영향을 미치는 가장 큰 요인은 자외선과 체내 호르몬 분비 정도이다. Melanin, melanoid, carotene and hemoglobin are the most important factors affecting skin color. Among them, melanin is the most important factor affecting the biosynthesis of melanin.
멜라닌은 자외선을 흡수 또는 산란시켜 자외선으로부터 피부가 손상되는 것을 방지하는데 큰 역할을 하는데, 특별한 최대 흡수 파장이 없고 전 영역의 빛을 흡수한다. 또한 활성 산소종을 제거하는 기능이 탁월하나, 때로는 멜라닌 자체가 활성 산소를 발생시키기도 하며, 멜라닌 구조 내의 카테콜이나 퀴논에 의하여 다른 물질을 환원시키거나 산화시키고, 멜라닌 자체가 자유라디칼의 성질을 나타내기도 한다.Melanin absorbs or scatters ultraviolet light and plays a major role in preventing damage to the skin from ultraviolet rays. It does not have a specific maximum absorption wavelength and absorbs light in all areas. In addition, it has excellent ability to remove reactive oxygen species, sometimes melanin itself generates active oxygen, and other substances are reduced or oxidized by catechol or quinone in the melanin structure, and melanin itself shows free radical properties Pray.
멜라닌의 생합성은 아미노산의 일종인 티로신이 멜라닌 형성 세포의 멜라노좀에서 티로시나제에 의해 산화되어 디하이드록시 페닐알라닌 (dihydroxy phenylalanine)으로 전환되는 것을 시작으로 계속되는 일련의 산화 과정을 거쳐 갈색 (pheomelanin), 흑색 (eumelanin)의 중합체로 형성된다.The biosynthesis of melanin begins with the conversion of tyrosine, an amino acid, into melanosomes of melanocyte-forming melanosomes by tyrosinase and conversion to dihydroxy phenylalanine, followed by a series of oxidation processes to form pheomelanin, eumelanin.
이러한 생합성 과정은 멜라노좀이라는 특수한 형태의 갈색 세포 내 소기관에서 진행되며 멜라닌 과립을 포함한 멜라노좀은 핵 주변 부위에서 수지상 돌기 끝부분으로 이동, 각질 세포의 식세포 작용에 의해 세포질 내로 이동하고 이들은 각질 세포의 핵 주변에 축적된다.This biosynthesis process is carried out in a special form of melanocyte in the brown intracellular organelle. The melanomas, including melanin granules, migrate from the nucleus to the tip of the dendritic process, and migrate into the cytoplasm by phagocytosis of keratinocytes. It accumulates around the nucleus.
멜라닌의 합성과 멜라노좀의 수, 주위의 각질 세포로의 이동은 부분적으로 호르몬과 자외선 등에 영향을 받고 일차적으로는 유전적인 영향을 크게 받는다. 그 밖에 티로시나제의 발현 및 멜라닌의 합성, 전송에 관여하는 세포내 조절인자인 싸이토카인 (cytokine), 구리, 아연, 철 등의 금속 이온 및 인터페론, 프로스타글란딘, 히스타민 등이 관여하는 것으로 알려져 있다.The synthesis of melanin, the number of melanosomes, and the migration to keratinocytes in the periphery are partially affected by hormones and ultraviolet rays, and are primarily affected by genetics. In addition, it is known that interleukins, prostaglandins, histamines, and the like are involved in the expression of tyrosinase and cytokine, which is an intracellular regulator involved in the synthesis and transmission of melanin, and metal ions such as copper, zinc and iron.
이미 아스코르빈산 (일본특개평 4-9320), 하이드로퀴논 (일본특개평-192062), 코직산 (일본특개소 56-7710), 알부틴 (일본특개평 4-93150) 및 일부의 추출물 등이 티로시나제 저해 활성을 가지고 있어 미백 화장료로 이용되고 있으나 화장품 제형 중에서의 안정성이 낮으므로 분해되어 착색되거나, 이취의 발생, 생체 레벨에서의 효능, 효과의 불분명 및 안전성 문제 등으로 그 사용이 제한되고 있는 실정이다. 그리고 상기한 물질들은 그 티로시나제 억제 효과가 입증되었으나 실제 생체 레벨과 유사한 실험에서는 그 효과가 낮게 나타난다. 따라서, 생체 레벨과 유사한 흑색종 세포 배양에 의한 저해효과 평가가 요구되고 있는 실정이다. 또한, 하이드로퀴논은 발암성 물질로 규정되어 화장품에서는 그 사용이 금지 또는 제한되고 있다. 코직산과 아스코르빈산은 매우 불안정한 물질이다. 상기 성분들을 소량 함유한 화장료는 실온에서 수 주일동안 보관하면 갈변 현상이 발생한다.(Japanese Patent Laid-open No. 4-9320), hydroquinone (Japanese Patent Laid-Open No. 192062), kojic acid (Japanese Patent Laid-open No. 56-7710), arbutin Activity, and is used as a whitening cosmetic. However, since it is low in stability in cosmetic formulations, its use is restricted due to decomposition and coloring, generation of odor, efficacy at a living body level, unclear effect and safety problem. These substances have proved their tyrosinase inhibitory effect, but their effect is lower in experiments similar to actual living body level. Therefore, there is a demand for evaluation of the inhibitory effect by melanoma cell culture similar to a living body level. Hydroquinone is also defined as a carcinogenic substance and its use in cosmetics is prohibited or restricted. Kojic acid and ascorbic acid are very unstable substances. When a cosmetic containing a small amount of the above components is kept at room temperature for several weeks, browning occurs.
이러한 여러가지 문제점을 해결하기 위하여, 최근 여러 화학 물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 화장품이 많이 개발되고 있다. 천연 재료는 피부에 부작용이 적을 뿐만 아니라, 최근 천연 재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발 가치가 한층 늘어나고 있다. In order to solve these various problems, recently, many cosmetics using natural products have been developed to reduce skin irritation caused by various chemical substances and the like. Natural materials are not only less harmful to the skin, but also have increased their value as a raw material for cosmetics due to the recent popularity of cosmetics using natural materials.
이에, 본 발명자들은 이제까지 알려지지 않은 여러 천연물들에 있어서 화장품으로의 응용 가능성을 연구한 결과, 덩굴식물인 으름덩굴을 선정하고 이로부터 추출물을 제조하여, 피부 항산화 효과, MMP-1 생성 억제 효과, 콜라겐 합성 증진 효과, 멜라닌 생성 억제 효과, 보습효과, 방부효과를 측정한 결과, 그 효능이 매우 우수하므로 화장품으로서의 효능을 기대할 수 있다는 것을 발견하게 되었다.As a result of studying applicability of cosmetics to various natural products which have not yet been known, the present inventors have selected a vine plant as a vine, and produced an extract therefrom, and found skin antioxidative effect, inhibitory effect on MMP-1 production, The inventors of the present invention have found that the efficacy of a cosmetic product can be expected because it is highly effective as a result of measuring synthetic enhancing effect, melanin production inhibiting effect, moisturizing effect and preservative effect.
본 발명의 목적은 으름덩굴 추출물을 함유하여 피부 항산화 효과, MMP-1 생성 억제 효과, 콜라겐 합성 증진 효과, 멜라닌 생성 억제 효과, 방부효과, 보습효과 또는 피부 주름개선 효과를 나타내는 화장료 조성물을 제공하는데 있다.It is an object of the present invention to provide a cosmetic composition which contains a moss extract to exhibit skin antioxidative effect, inhibitory effect on MMP-1 production, collagen synthesis enhancing effect, melanin formation inhibitory effect, preservative effect, moisturizing effect or skin wrinkle improving effect .
본 발명의 또 다른 목적은 상기 으름덩굴 추출물을 함유하는 화장료 조성물을 이용하는 화장 방법을 제공하는데 있다.It is still another object of the present invention to provide a cosmetic method using a cosmetic composition containing the above-mentioned vinegar extract.
따라서, 상기와 같은 본 발명의 목적은 으름덩굴 추출물을 유효성분으로 함유하는 화장료 조성물에 의해 달성된다. Therefore, the object of the present invention as described above is achieved by a cosmetic composition comprising an extract of Aspergillus oryzae as an active ingredient.
바람직하게는, 상기 화장료 조성물은 피부노화방지용이다.Preferably, the cosmetic composition is for preventing skin aging.
바람직하게는, 상기 화장료 조성물은 피부주름 개선용이다.Preferably, the cosmetic composition is for improving skin wrinkles.
바람직하게는, 상기 화장료 조성물은 피부 미백용이다.Preferably, the cosmetic composition is for skin whitening.
바람직하게는, 상기 화장료 조성물은 방부효과를 갖는다.Preferably, the cosmetic composition has a preservative effect.
바람직하게는, 상기 화장료 조성물은 보습용이다.Preferably, the cosmetic composition is for moisturizing.
바람직하게는, 상기 으름덩굴 추출물은 상기 화장료 조성물의 전체 중량에 대하여 0.0001 ~ 30.0 중량% 함유된다.Preferably, the myrtle extract is contained in an amount of 0.0001 to 30.0% by weight based on the total weight of the cosmetic composition.
바람직하게는, 상기 으름덩굴 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 클로로포름, 부틸 아세테이트, 디에틸에테르, 디클로로메탄, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법을 이용하여 추출한다.Preferably, the vinegar extract is selected from the group consisting of (a) water, an anhydrous or a lower alcohol having 1-4 carbon atoms, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane , Hexane, and mixtures thereof, and (b) supercritical extraction.
바람직하게는, 상기 화장료 조성물은 피부 항산화 효과, MMP-1 생성 억제 효과, 콜라겐 합성 증진 효과, 멜라닌 생성 억제 효과, 보습효과, 피부 주름 개선효과를 나타낸다.Preferably, the cosmetic composition exhibits skin antioxidant effect, MMP-1 production inhibiting effect, collagen synthesis enhancing effect, melanin formation inhibiting effect, moisturizing effect, and skin wrinkle improving effect.
바람직하게는, 상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 클렌징, 오일, 분말파운데이션, 유탁액파운데이션, 왁스파운데이션, 팩, 마사지크림 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는다.Preferably, the cosmetic composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray ≪ / RTI >
본 발명의 또 다른 목적은 상기 화장료 조성물을 이용하는 화장 방법에 의해 달성된다.Another object of the present invention is achieved by a cosmetic method using the cosmetic composition.
본 발명에 따른 으름덩굴 추출물은 MMP-1 생성 억제 효과(실험예 1), 콜라겐 합성 증진 효과(실험예 2), 멜라닌 생성 억제 효과(실험예 3), 보습 효과(실험예 4), 방부효과(실험예 5),및 주름개선 효과(실험예 6)를 갖는다.The collagen extract according to the present invention is effective for inhibiting MMP-1 production (Experimental Example 1), collagen synthesis enhancing effect (Experimental Example 2), melanin formation inhibitory effect (Experimental Example 3), moisturizing effect (Experimental Example 4) (Experimental Example 5), and a wrinkle-improving effect (Experimental Example 6).
또한, 본 발명에 따르면, 으름덩굴 추출물을 효능을 극대화하기 위해 초음파 및 초임계추출을 통해 항산화 효과, MMP-1 생성억제 효과, 콜라겐 합성 증진 효과, 멜라닌 생성억제 효과를 더욱 증진시켜준다.In addition, according to the present invention, in order to maximize the efficacy of the Aspergillus oryzae extract, it is possible to further enhance the antioxidative effect, the inhibitory effect on MMP-1 production, the collagen synthesis inhibitory effect and the melanin production inhibitory effect through ultrasound and supercritical extraction.
본 발명의 화장료 조성물 중 유효 성분으로 사용되는 으름덩굴(Akebia quinata)은 으름 또는 어름나무라고도 한다. 산과 들에서 자라며 길이는 약 5m이다. 가지는 털이 없고 갈색이고, 잎은 묵은 가지에서는 무리지어 나고 새가지에서는 어긋나며 손바닥 모양의 겹잎이다. 꽃은 암수한그루로서 꽃잎은 없고 3개의 꽃받침조각이 꽃잎같이 보인다. 열매는 장과로서 긴 타원형이고 10월에 자줏빛을 띤 갈색으로 익는다. 한방에서는 뿌리와 줄기가 소염, 이뇨, 통경 작용에 효능이 있으므로 약재로 쓴다. 한국(황해도 이남), 일본, 중국 등지에 분포한다. In the cosmetic composition of the present invention, Akebia quinata ) is also known as the true or dead tree. It grows in mountains and fields and is about 5 meters long. The branch is hairless and brown, the leaves are clustered in old branches, alternate in new branches, and palm-like compound leaves. The flower is a single male, with no petals, and three calyx pieces look like petals. The fruit is long oval in shape and ripens in purplish brown in October. In oriental medicine, roots and stems are used as medicines because they are effective for anti-inflammatory, diuretic, and penetration. It is distributed in Korea (south of Hwanghae Island), Japan, and China.
본 발명에 있어서, 으름덩굴 추출물은 으름덩굴의 다양한 기관 또는 부분(예: 잎, 뿌리, 줄기, 가지, 여린가지, 껍질 및 종자 등)으로부터 추출하여 얻은 것을 의미하고, 바람직하게는 잎, 여린가지, 줄기, 가지, 껍질 또는 뿌리로부터 얻은 추출물이고, 보다 바람직하게는 잎, 여린가지 또는 뿌리로부터 얻은 추출물이며, 가장 바람직하게는 잎과 여린가지로부터 얻은 추출물을 의미한다.In the present invention, the Crane Extract is obtained by extracting from various organs or parts (e.g., leaves, roots, stems, branches, limbs, bark, seeds and the like) of Crane Vine, An extract obtained from a stem, a branch, a bark or a root, more preferably an extract obtained from a leaf, a chewing gum or a root, and most preferably an extract obtained from a leaf and a chewing gum.
또한, 본 발명의 으름덩굴 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건 하에서, 통상적인 용매를 사용하여 제조될 수 있으나, 바람직하게는 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올(예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 용매를 이용한 용매 추출법 (b) 이산화탄소에 의한 감압 및 고온에 의한 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출할 수 있고, 가장 바람직하게는 추출용매를 이용한 용매 추출법을 이용한다. In addition, the Crane Extract of the present invention can be produced by using conventional solvents known in the art, that is, under the conditions of ordinary temperature and pressure, but preferably using (a) water, (Such as methanol, ethanol, propanol and butanol) having 1 to 4 carbon atoms, propylene glycol, 1,3-butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloro (B) solvent extraction using a solvent selected from the group consisting of methanol, chloroform, hexane, and mixtures thereof, (b) supercritical extraction with carbon dioxide and supercritical extraction with high temperature, or (c) A solvent extraction method using an extraction solvent is used.
본 발명에서 으름덩굴 추출물은 다양한 추출용매, 예를 들어, 물, 탄소수 1-4의 무수 또는 함수 저급 알코올 (예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 1종 이상의 추출 용매를 사용하여 얻을 수 있으며, 바람직하게는 에탄올, 70%(v/v) 에탄올 또는 물을 사용하여 얻어진 것이고, 가장 바람직하게는 70%(v/v) 에탄올을 사용하여 얻어진 것이다. In the present invention, the vinegar extract may contain various extraction solvents, for example, water, anhydrous or lower alcohols having 1-4 carbon atoms (e.g., methanol, ethanol, propanol and butanol), propylene glycol, It may be obtained by using at least one extraction solvent selected from the group consisting of glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane and mixtures thereof, % (v / v) ethanol or water, and most preferably 70% (v / v) ethanol.
한편, 본 발명의 으름덩굴 추출물은 상기한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다.On the other hand, it is obvious to those skilled in the art that the extract of Vinegar of the present invention can obtain an extract having substantially the same effect not only by the aforementioned extraction solvent but also by using other extraction solvent.
또한, 본 발명의 으름덩굴 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 및 발효 과정을 거친 추출물도 포함한다. 예컨대, 이산화탄소에 의한 감압, 고온에 의한 초임계추출법에 의한 추출, 초음파를 이용한 추출법에 의한 추출, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리하거나 자연 상태나 각종 미생물을 이용한 발효산물에 의한 추출물 등, 추가적으로 실시된 다양한 정제 및 추출방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함된다.In addition, the crane extract of the present invention includes not only the extract obtained by the above-mentioned extraction solvent, but also the extract obtained through ordinary purification and fermentation process. For example, decompression by carbon dioxide, extraction by supercritical extraction at high temperature, extraction by extraction using ultrasound, separation by ultrafiltration membrane with constant molecular weight cut-off value, various chromatography (size, charge, hydrophobic or affinity And the active fraction obtained through various purification and extraction methods, such as an extract obtained by fermentation products using natural or various microorganisms, are also included in the extract of the present invention.
또한, 본 발명은 상기 추출물이 상온에서 냉침, 가열 여과하여 얻어진 액상물, 추가로 용매를 감압농축 또는 동결 건조하여 얻은 것임을 특징으로 하는 화장료 조성물을 제공한다. Further, the present invention provides a cosmetic composition characterized in that the above extract is obtained by liquid-freezing obtained by cold-pressing and heating filtration at room temperature, and further by concentrating or lyophilizing the solvent under reduced pressure.
상기 이산화탄소에 의한 감압, 고온에 의한 초임계추출법에 의한 추출법은 초임계 유체 추출법(supercritical fluid extraction)을 의미하는 것으로, 일반적으로 초임계 유체는 기체가 고온 고압 조건에서 임계점에 도달하였을 때 갖는 액체 및 기체의 성질을 지니고 있으며, 화학적으로 비극성 용매와 유사한 극성을 지니고 있으며 이러한 특성으로 인해 초임계 유체는 지용성 물질의 추출에 사용되고 있다(J. Chromatogr. A. 1998;479:200-205).The supercritical fluid extraction refers to supercritical fluid extraction. Generally, the supercritical fluid is extracted from the liquid and the liquid when the gas reaches the critical point at high temperature and high pressure. (J. Chromatogr. A. 1998; 479: 200-205). In addition, it has been reported that the supercritical fluid has a polarity similar to that of a nonpolar solvent.
이산화탄소는 초임계 유체기기의 작동으로 압력 및 온도가 임계점까지 이르는 과정을 거치면서 액체 및 기체 성질을 동시에 지닌 초임계 유체가 되고 그 결과 지용성 용질에 대한 용해도가 증가한다. 초임계 이산화탄소가 일정량의 시료를 함유한 추출 용기를 통과하게 되면 시료에 함유된 지용성 물질은 초임계 이산화탄소에 추출되어 나온다.Carbon dioxide is a supercritical fluid with both liquid and gaseous nature, with the operation of supercritical fluid equipment reaching its critical pressure and temperature, resulting in increased solubility in fat-soluble solutes. When supercritical carbon dioxide passes through an extraction vessel containing a certain amount of sample, the lipophilic substance contained in the sample is extracted into supercritical carbon dioxide.
지용성 물질을 추출한 후 추출 용기에 남아있는 시료에 다시 소량의 공용매가 함유된 초임계 이산화탄소를 흘려 통과시키면 순수한 초임계 이산화탄소만으로는 추출되지 않았던 성분들이 추출되어 나오게 할 수 있다. When the supernatant carbon dioxide containing a small amount of cosolvent is passed through the sample remaining in the extraction vessel after extracting the lipid-soluble substance, components that were not extracted by pure supercritical carbon dioxide can be extracted.
본 발명의 초임계추출법에 사용되는 초임계 유체는 초임계 이산화탄소 또는 이산화탄소에 추가적으로 공용매를 혼합한 혼합유체를 사용함으로써 효과적으로 유효 성분을 추출할 수 있다.The supercritical fluid used in the supercritical extraction method of the present invention can effectively extract an active ingredient by using a mixed fluid in which a cosolvent is further mixed with supercritical carbon dioxide or carbon dioxide.
이러한 공용매는 클로로포름, 에탄올, 메탄올, 물, 에틸아세테이트, 헥산 및 디에틸에테르로 이루어진 군에서 선택되는 1종 또는 2종 이상의 혼합물을 사용할 수 있다.These co-solvents may be used alone or in admixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether.
추출된 시료는 대부분 이산화탄소를 함유하고 있는데 이산화탄소는 실온에서 공기 중으로 휘발되므로 상기 방법으로 얻은 추출물을 화장료 조성물로서 사용할 수 있으며, 공용매는 감압증발기로 제거할 수 있다.Most of the extracted samples contain carbon dioxide. Since the carbon dioxide is volatilized into air at room temperature, the extract obtained by the above method can be used as a cosmetic composition, and the cosolvent can be removed by a reduced pressure evaporator.
또한 상기 초음파 추출법은 초음파 진동에 의해 발생되는 에너지를 이용하는 추출방법으로, 초음파가 수용성 용매 속에서 시료에 포함된 불용성인 용매를 파괴시킬 수 있으며, 이때 발생되는 높은 국부온도로 인하여 주위에 위치하는 반응물 입자들의 운동에너지를 크게 하기 때문에 반응에 필요한 충분한 에너지를 얻게 되고, 초음파 에너지의 충격효과로 높은 압력을 유도하여 시료에 함유된 물질과 용매의 혼합 효과를 높여주어 추출효율을 증가시키게 된다. In addition, the ultrasonic extraction method is an extraction method using energy generated by ultrasonic vibration. Ultrasonic waves can destroy an insoluble solvent contained in a sample in a water-soluble solvent. Due to the high local temperature generated at this time, Since the kinetic energy of the particles is increased, sufficient energy required for the reaction is obtained. By inducing the high pressure by the shock effect of the ultrasonic energy, the mixing efficiency of the substance contained in the sample and the solvent is increased, thereby increasing the extraction efficiency.
초음파 추출법에 사용할 수 있는 추출용매는 클로로포름, 에탄올, 메탄올, 물, 에틸아세테이트, 헥산 및 디에틸에테르로 이루어진 군에서 선택되는 1종 또는 2종 이상의 혼합물을 사용할 수 있다. 추출된 시료는 진공 여과하여 여과액을 회수한 후 감압증발기로 제거하고, 동결 건조하는 통상의 추출물 제조방법을 통해 추출물을 얻을 수 있다. As the extraction solvent which can be used for the ultrasonic extraction method, one or a mixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether can be used. The extracted sample is recovered by vacuum filtration, and the filtrate is recovered, and the extract is removed by a vacuum evaporator and freeze-dried to obtain an extract.
본 발명에 따른 으름덩굴 추출물은 발효과정을 거친 추출물도 포함하는데, 으름덩굴의 발효추출물은 다음과 같이 제조할 수 있다. 으름덩굴을 100~500메쉬 정도로 미세하게 파쇄 한 다음 통상적인 미생물 배양액을 1~50g/L를 첨가하고 효모균주 또는 유산균등의 미생물을 10,000~100,000 cfu/L의 양으로 첨가한다. 배양온도는 30~37℃의 통상적인 미생물 배양조건으로 배양한다. pH는 5~7로 호기적 또는 통상 혐기(anaerobic)적인 조건으로 약 5내지 10일간 배양한다. 이후 숙성 및 여과를 통해 얻을 수 있다.The crane extract according to the present invention includes an extract obtained through fermentation, and the fermented extract of Crane can be prepared as follows. The crushed vine is finely crushed to a size of about 100 to 500 mesh, then 1 to 50 g / L of a conventional microorganism culture solution is added, and microorganisms such as yeast strains or lactic acid bacteria are added in an amount of 10,000 to 100,000 cfu / L. The culture temperature is 30 to 37 ° C. The pH is 5 to 7 and aerobic or anaerobic conditions are maintained for about 5 to 10 days. Which can be obtained through aging and filtration.
본 발명에 따르면, 상기 으름덩굴 추출물은 화장료 조성물의 전체 중량에 대해서 0.001 ~ 30.0 중량% 함유되며, 더욱 바람직하게는, 상기 으름덩굴 추출물은 화장료 조성물의 전체 중량에 대해서 0.01 ~ 10 중량% 함유되는 것을 특징으로 한다. 상기 추출물의 함량이 0.001 중량% 미만인 경우에는 피부 개선 효과가 나타나지 않으며, 30.0 중량%를 초과하는 경우에는 함유량 증가에 대한 피부 개선 효과 증대 정도가 미미하며, 제형상의 안전 및 안정성에 문제가 있으며 경제적이지도 못하다. According to the present invention, it is preferable that the myrtle extract is contained in an amount of 0.001 to 30.0 wt% based on the total weight of the cosmetic composition, more preferably the myrtle extract is contained in an amount of 0.01 to 10 wt% . When the content of the extract is less than 0.001% by weight, the effect of improving the skin is not exhibited. When the content of the extract is more than 30.0% by weight, the degree of improvement of the skin against the increase of the content is insignificant, It is not even.
따라서, 이러한 다양한 기능을 가진 으름덩굴 추출물을 포함하는 본 발명의 화장료 조성물은 우수한 항산화 효과, 피부노화 방지효과, 콜라겐 합성 증진 효과, MMP-1 생성 억제 효과, 피부주름 개선 효과, 피부 미백 효과, 멜라닌 생성 억제 효과, 보습효과 및 방부효과를 갖는 것을 특징으로 한다.Therefore, the cosmetic composition of the present invention comprising the moss vine extract having various functions of the present invention has excellent antioxidative effect, skin aging prevention effect, collagen synthesis promotion effect, MMP-1 production inhibitory effect, skin wrinkle improvement effect, skin whitening effect, melanin A production-inhibiting effect, a moisturizing effect, and a preservative effect.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서 상기 유효 성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The ingredients contained in the cosmetic composition of the present invention may contain, as an active ingredient, the ingredients commonly used in cosmetic compositions in addition to the above-mentioned effective ingredients, and may contain conventional ingredients such as antioxidants, stabilizers, solubilizers, vitamins, Supplements, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 팩, 마사지크림 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, , Oil, powdered foundation, emulsion foundation, wax foundation, pack, massage cream and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Alkylamido betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 제형 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클렌징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비 함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing formulation or a surfactant-free cleansing formulation, it may be applied to the skin and then wiped off, washed or rinsed with water. The surfactant-containing cleansing formulation may be a cleansing foam, a cleansing water, a cleansing towel and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.
한편, 본 발명의 화장 방법은 본 발명의 화장료 조성물을 이용하는 모든 화장 방법을 일컫는다. 즉, 화장료 조성물을 이용하는 당업계에 공지된 모든 방법이 본 발명의 화장 방법에 속한다.On the other hand, the cosmetic process of the present invention refers to all cosmetic processes using the cosmetic composition of the present invention. That is, all methods known in the art using a cosmetic composition belong to the cosmetic method of the present invention.
본 발명의 화장료 조성물은 단독 또는 중복하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복하여 사용할 수 있다. 또한 본 발명에 따른 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition of the present invention may be used alone or in combination, or may be used in combination with other cosmetic compositions other than the present invention. The cosmetic composition according to the present invention may be used according to a conventional method of use, and may be used in a number of times depending on the skin condition or taste of the user.
본 발명의 으름덩굴 추출물을 포함하는 화장료 조성물을 이용하는 화장방법을 수행하면, 피부 항산화 효과, MMP-1 생성 억제 효과, 콜라겐 합성 증진 효과, 멜라닌 생성 억제 효과와 보습효과, 방부 효과 및 피부 주름개선 효과를 얻을 수 있다.By carrying out the cosmetic method using the cosmetic composition comprising the crude extract of the present invention, skin antioxidative effect, MMP-1 production inhibitory effect, collagen synthesis promotion effect, melanin formation inhibitory effect and moisturizing effect, preservative effect, Can be obtained.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
제조예Manufacturing example 1: 으름덩굴 추출물 제조 1: Manufacture of Crane Vine Extract
세절하여 음건한 으름덩굴 줄기 100g을 5배량의 70% (V/V) 에탄올 수용액 으로 5시간씩 3회 환류 추출하고 냉침한 후, 와트만(Whatman) #2 여과지로 여과하였다. 여과된 추출물을 50 ℃ 이하에서 감압 농축 및 동결 건조하였다.
100 g of the shrubs of the shrubs were washed with 5 times of 70% (v / v) aqueous ethanol solution for 5 hours, refluxed 3 times, and filtered through Whatman # 2 filter paper. The filtered extract was concentrated under reduced pressure and freeze-dried at 50 DEG C or lower.
제조예Manufacturing example 2~4. 으름덩굴 2 to 4. Vine 초임계Supercritical 유체 추출물 및 초음파 추출물 제조 Manufacture of fluid extracts and ultrasonic extracts
으름덩굴 줄기 100g을 통상적인 초임계 추출법(약 60℃의 온도에서 약 300 기압의 압력 하에 초임계 상태에서 공용매로서 올리브오일을 이용하여 추출함)으로 추출하여 초임계 추출물을 얻었다(제조예 2). 으름덩굴 줄기 100g을 초음파(슈퍼노닉 초음파기기를 이용하여 25KHz의 강도로 30℃에서 약 2시간 동안 추출)를 이용한 추출을 통해 추출물을 얻었다(제조예 3 및 4). 제조예 3의 경우에는 공용매로 에탄올를 사용하였으며 제조예 4에서는 공용매로서 정제수를 사용하였다.
(100 g) was extracted with a conventional supercritical extraction method (extracting with olive oil as a co-solvent under a pressure of about 300 atm at a temperature of about 60 DEG C under supercritical conditions) to obtain a supercritical extract (Preparation Example 2 ). The extracts were obtained by extracting 100 g of Rhizome with ultrasound (extraction with a SuperNonic ultrasonic device at 25 KHz at 30 캜 for about 2 hours) (Production Examples 3 and 4). In Production Example 3, ethanol was used as a cosolvent, and in Production Example 4, purified water was used as a cosolvent.
실험예Experimental Example 1. 으름덩굴 추출물의 1. Creeping Vine Extract MMPMMP -1 생성 억제 효과-1 production inhibitory effect
본 실험예 1은 제조예 1~4 에서 수득한 으름덩굴 추출물이 콜라겐 분해효소인 MMP-1 생성을 억제하는 효과를 측정하였다.In Experimental Example 1, the effect of inhibiting the production of MMP-1, a collagenase, was evaluated by the crude extracts obtained in Production Examples 1 to 4.
인간 정상 피부 세포인 섬유아세포 (한국 세포주 은행, 대한민국)를 48-웰 마이크로 플레이트(Nunc, 덴마크)에 각 웰당 1× 106 세포가 되도록 접종하고, DMEM 배지(Sigma, 미합중국) 및 37℃의 조건에서 24시간 동안 배양한 후 상기 제조예 1,2 의 으름덩굴 추출물을 첨가한 무혈청 DMEM 배지 및 대조군으로 으름덩굴 추출물이 포함되지 않은 무혈청 DMEM 배지에서 48시간 동안 추가로 배양하였다. Human normal skin cells were inoculated into a 48-well microplate (Nunc, Denmark) at a concentration of 1 × 10 6 cells per well and cultured in DMEM medium (Sigma, USA) and 37 ° C For 24 hours. Then, the cells were further cultured in serum-free DMEM medium supplemented with Aspergillus niger extracts of Preparation Examples 1 and 2 and in serum-free DMEM medium containing no myrtle extract for 48 hours.
배양 후, 각 웰의 상층액을 모아 MMP-1 분석 킷트(Amersham, 미합중국)를 이용하여 새로 합성된 MMP-1의 양(ng/㎖)을 측정하고, 하기 수학식 3에 따라 MMP-1 생성 억제율(%)을 계산하였으며, 그 결과를 표 1에 나타내었다.After culturing, the supernatant of each well was collected and the amount (ng / ml) of the newly synthesized MMP-1 was measured using an MMP-1 assay kit (Amersham, USA) The inhibition rate (%) was calculated and the results are shown in Table 1.
[[ 수학식Equation 1] One]
시료명
Name of sample
농도
(ppm)process
density
(ppm)
으름덩굴 추출물
Vine Extract
상기 표 1의 결과에서 보는 바와 같이, 본 발명의 으름덩굴 추출물은 농도의존적으로 MMP-1의 생성을 억제(MMP-1 활성 억제)시키는 것을 확인할 수 있었다. 특히 제조예 1에 의해서 제조된 으름덩굴 추출물이 다른 제조예보다 효과가 좋은 것을 확인 하였다. MMP-1 생성 억제효과가 있는 것으로 알려진 물질인 TGF-β의 농도(200nM)와 본원발명의 으름덩굴 추출물의 농도(300ppm) 차이를 감안해도, 여러 종류의 물질이 혼합된 추출물 수준에서 상기와 같은 정도의 MMP-1 억제율을 나타낸 것은 본원발명의 으름덩굴 추출물은 MMP-1 생성 억제 효과가 있다는 것을 보여준다.As shown in the results of Table 1, it was confirmed that the Crane extract of the present invention inhibits MMP-1 production (inhibits MMP-1 activity) in a concentration-dependent manner. In particular, it was confirmed that the extract of Crassulaceae produced by Preparation Example 1 was more effective than the other preparations. Even considering the difference between the concentration of TGF-beta (200 nM), which is known to have an inhibitory effect on MMP-1 production, and the concentration (300 ppm) of the vinegar extract of the present invention, The inhibition of MMP-1 production by the myrtle extract of the present invention was shown to be effective in inhibiting MMP-1 production.
실험예Experimental Example 2. 으름덩굴 추출물의 콜라겐 합성 증진 효과 2. Enhancement of Collagen Synthesis Effect of Crane Vine Extract
인간 정상 상피 세포인 섬유아세포를 48-웰 마이크로 플레이트에 각 웰당 1 x 106 세포가 되도록 접종하고, DMEM 배지에서 24시간 동안 배양하였다. 상기 제조예 1~4에 의해 제조된 으름덩굴 추출물을 첨가한 무혈청 DMEM 배지 및 대조군으로 으름덩굴 추출물이 포함되지 않은 무혈청 DMEM 배지에서 48시간 동안 추가로 배양하였다. 배양 후, 각 웰의 상층액을 모아 콜라겐 키트(Takara, 일본)를 이용하여 프로콜라겐 (procollagen) 타입 I C-펩타이드 (PICP) 양을 측정하여 ng/㎖ 환산하였으며, 이에 의해 합성된 콜라겐 양을 측정하였다. 콜라겐 생합성 증가율(%)은 하기 수학식 3에 따라 계산하였으며, 그 결과를 표 2에 나타내었다. Human normal epithelial cells, fibroblasts, were inoculated into 48-well microplates at a density of 1 x 10 6 cells per well and cultured in DMEM medium for 24 hours. The cells were further cultured in serum-free DMEM medium supplemented with Crassostrea japonica extract prepared in Preparation Examples 1 to 4 and in serum-free DMEM medium containing no myrtle extract for 48 hours as a control. After the incubation, the supernatant of each well was collected, and the amount of procollagen type I C-peptide (PICP) was measured using a collagen kit (Takara, Japan) and converted into ng / Respectively. The rate of increase in collagen biosynthesis (%) was calculated according to the following equation (3).
[[ 수학식Equation 2] 2]
시료명
Name of sample
농도
(ppm)process
density
(ppm)
으름
덩굴
추출물
The
vine
extract
표 2에 따르면, 본 발명의 제조예 1~4에 의해 제조된 정제된 으름덩굴 추출물의 콜라겐 생합성율이 농도의존적으로 증가하는 것을 확인할 수 있었다.특히 제조예 1 의해 제조된 추출물이 효과가 다른 제조예 추출물보다 효과가 더 좋은 것을 확인 하였다.
According to the results shown in Table 2, it was confirmed that the collagen biosynthesis rate of the purified crane extracts prepared in Production Examples 1 to 4 of the present invention was increased in a concentration-dependent manner. The results of this study are as follows.
실험예Experimental Example 3: 으름덩굴 추출물의 B16F1 멜라닌형성세포를 이용한 멜라닌 생성 억제효과 3: Melanin formation inhibition effect of B16F1 melanocyte-forming cells of Crane extract
본 실험예 3는 상기 제조예 1~4 에서 수득한 으름덩굴 추출물의 미백 효과를 확인하기 위해 B16F1 멜라닌 형성 세포에 대한 멜라닌 생성 억제 정도를 보고 미백 효과를 판단한 것이다. 본 실험예 3에 사용된 B16F1 멜라닌 형성 세포는 마우스에서 유래한 세포균주이며, 멜라닌이라는 흑색 색소를 분비하는 세포이다. Experimental Example 3 was conducted to examine the whitening effect of the crude extract obtained in Production Examples 1 to 4 and to determine the inhibitory effect of melanin on B16F1 melanin-forming cells. The B16F1 melanin-forming cell used in Experimental Example 3 is a cell strain derived from a mouse, and is a cell that secretes a melanin pigment called melanin.
이 세포의 인공 배양 중에 시료를 처리하여 멜라닌 흑색 색소가 감소하는 정도를 비교 평가하였다. 본 실험예에 사용된 B16F1 멜라닌 형성 세포는 ATCC(American Type Culture Collection)로부터 분양받아 사용하였다.During the artificial culture of these cells, samples were treated to compare the degree of reduction of melanin pigment. The B16F1 melanin-forming cells used in this experiment were purchased from the American Type Culture Collection (ATCC).
B16F1 멜라닌 형성 세포의 멜라닌 생합성 억제 효과 측정은 다음과 같이 행하였다. Melanin biosynthesis inhibitory effect of B16F1 melanin-forming cells was measured as follows.
B16F1 멜라닌 형성 세포를 6웰 플레이트에 각 웰당 2 X 105 농도로 분주하고 세포를 부착시킨 후 독성을 유발하지 않는 농도로 제조예 1에 따른 으름덩굴 추출물을 처리하여 72시간 동안 배양하였다. 72시간 배양 후 세포를 트립신-EDTA로 떼어낸 후 세포수를 측정한 다음 원심분리하여 세포를 회수하였다. 세포 내 멜라닌의 정량은 로탄(Lotan: Cancer Res., 40: 3345-3350, 1980)의 방법을 약간 변형하여 실시하였다. 셀 펠릿을 PBS로 1회 세척한 후 균질화 버퍼액(50 mM 소듐 포스페이트, pH 6.8, 1% Triton X-100, 2 mM PMSF) 1ml를 첨가하여 5분간 와류하여 세포를 파쇄하였다. 원심분리 (3,000 rpm, 10분)하여 얻은 세포 여액에 1N NaOH(10% DMSO)를 첨가하여 추출된 멜라닌을 용해한 후 마이크로 플레이트 판독기로 405 nm에서 멜라닌의 흡광도를 측정한 다음 멜라닌을 정량하여 시료의 멜라닌 생성 저해율(%)을 측정하였다. B16F1 멜라닌 형성 세포의 멜라닌 생성 저해율을 (%)은 하기 수학식 4에 의하여 계산하였으며, 그 결과를 표 3에 기재하였다. B16F1 melanogenesis cells were plated at 6 × 10 5 / well in a 6-well plate and cells were attached and cultured for 72 hours at a concentration that did not induce toxicity after treatment with Crassulaceae extract according to Preparation Example 1. After incubation for 72 hours, the cells were detached with trypsin-EDTA, the number of cells was measured, and the cells were recovered by centrifugation. Quantification of intracellular melanin was carried out with a slight modification of the method of Lotan (Cancer Res., 40: 3345-3350, 1980). Cell pellet was washed once with PBS, and 1 ml of homogenization buffer solution (50 mM sodium phosphate, pH 6.8, 1% Triton X-100, 2 mM PMSF) was added and vortexed for 5 minutes to disrupt the cells. After centrifugation (3,000 rpm, 10 min), 1N NaOH (10% DMSO) was added to the cell filtrate to dissolve the extracted melanin, and the absorbance of melanin was measured at 405 nm with a microplate reader. The inhibition rate (%) of melanin formation was measured. Melanin production inhibition rate (%) of B16F1 melanin-forming cells was calculated by the following formula (4), and the results are shown in Table 3 below.
[[ 수학식Equation 3] 3]
멜라닌 생성 저해율 (%) = [(A-B)/A] X 100Melanin formation inhibition rate (%) = [(A-B) / A] X 100
A : 시료를 첨가하지 않은 웰의 멜라닌 양 A: Amount of melanin in wells to which no sample was added
B : 시료를 첨가한 웰의 멜라닌 양B: Amount of melanin in the well to which the sample was added
시료명
Name of sample
농도
(ppm)process
density
(ppm)
으름
덩굴
추출물
The
vine
extract
상기 표 3의 결과에서 알 수 있듯이, 본 발명의 제조예 1~4에 의해 제조된 정제된 으름덩굴 추출물은 B16F1 멜라닌 형성 세포에서 멜라닌 생성을 크게 저해하는 것을 알 수 있었다.
As can be seen from the results of Table 3, it was found that the purified Crane extracts prepared by Production Examples 1 to 4 of the present invention significantly inhibited melanogenesis in B16F1 melanin-forming cells.
제형예Formulation Example 1 :으름덩굴 추출물을 함유하는 1: Containing virgin extract 화장료Cosmetics 조성물의 제조 Preparation of composition
으름덩굴 추출물을 포함하는 화장료는 제조예 1, 제조예 3 및 제조예4의 으름덩굴 추출물을 각각 포함하는 화장료(제형예 1,2,3)를 제조하였으며, 효능의 비교를 위해 으름덩굴 추출물 대신에 보습제로서 글리세린 및 1,3부틸렌글리콜을 포함하는 화장료 조성물(비교제형예 1), 보습제로서 글리세린 및 솔비톨을 포함하는 화장료 조성물(비교제형예 2), 추출물이나 보습제를 모두 포함하지 않는 화장료 조성물(비교제형예 3)을 하기 표 4에 나타내었다. Cosmetic preparations containing Form Vine Extract (Formulation Examples 1, 2 and 3) each containing the extract of Vinegar of Preparation Example 1, Preparation Example 3 and Preparation Example 4 were prepared. For comparison of efficacy, (Comparative Formulation Example 1) containing glycerin and 1,3-butylene glycol as moisturizing agents, a cosmetic composition containing glycerin and sorbitol as a moisturizing agent (Comparative Formulation Example 2), a cosmetic composition containing neither an extract nor a moisturizing agent (Comparative Formulation Example 3) are shown in Table 4 below.
(제조예 1)Vine Extract
(Production Example 1)
(제조예 3)Vine Extract
(Production Example 3)
(제조예 4)Vine Extract
(Production Example 4)
실험예Experimental Example 4 : 으름덩굴 추출물의 보습 효과 4: Moisturizing effect of mulberry extract
상기 제형예 1, 2, 3의 화장료 조성물에 대한 임상 보습 효과를 다음과 같이 측정하였다. 설문 조사를 통하여 피부가 건조하다고 느끼는 건강한 성인 남녀 120 명을 무작위로 20 명씩 6개 그룹 (A, B, C, D ,E 및 F)으로 나눈 후, A, B, C 그룹에는 제형예 1,2,3의 화장료 조성물을, D 그룹에는 각각 으름덩굴 추출물 대신에 보습제로서 글리세린 및 1,3부틸렌글리콜을 포함하는 화장료 조성물(비교제형예 1), E 그룹에는 보습제로서 글리세린 및 솔비톨을 포함하는 화장료 조성물(비교제형예 2)의 화장료 조성물을, F 그룹에는 보습제를 함유하지 않은 베이스 제형의 화장료 조성물(비교제형예3)을 각각 1일 2회씩 4주간 안면에 도포하게 하였다. 보습 효과는 실사용 시험 시작 후부터 매 2주간, 그리고 종료 후의 개선 효과를 Corneometer CM 820 (Corage +Khazaka, Germany)를 이용하여 평가하였다. 으름덩굴 추출물의 피부 보습 효과의 실험 결과는 하기 표 5에 나타내었다.The clinical moisturizing effects of the cosmetic compositions of Formulation Examples 1, 2 and 3 were measured as follows. A, B and C groups were divided into 6 groups (A, B, C, D, E and F) by randomly dividing 120 healthy men and women who feel skin dry through a questionnaire. (Comparative Formulation Example 1) containing glycerin and 1,3-butylene glycol as moisturizing agents instead of vinegar extracts (each of Comparative Formulation Example 1) in Group D, and glycerin and sorbitol as moisturizing agents in Group E The cosmetic composition of the cosmetic composition (Comparative Formulation Example 2) and the cosmetic composition of the base formulation (Comparative Formulation Example 3) containing no moisturizing agent were applied to the F group twice a day for four weeks respectively. The moisturizing effect was evaluated by Corneometer CM 820 (Corage + Khazaka, Germany) for every 2 weeks and after the start of the test. Experimental results of the skin moisturizing effect of Vinegar extract are shown in Table 5 below.
상기 표 5에 나타낸 바와 같이, 일반 다른 보습제를 함유한 화장료(비교제형예 1,2,3)와 비교하여도 본 발명의 으름덩굴 추출물 함유한 화장료(제형예 1, 2,3)의 보습효과가 우수함을 확인할 수 있었다. As shown in the above Table 5, the moisturizing effect of the cosmetic compositions (Formulation Examples 1, 2 and 3) containing the extract of Vinegar of the present invention (Comparative Formulations 1, 2 and 3) .
실험예Experimental Example 5: 으름덩굴 추출물의 방부 효과 5: Preservative effect of mulberry extract
으름덩굴 추출물의 항균 효과를 알아보기 위해, 하기 표 7의 조성으로 제조예 3 의 으름덩굴 추출물을 다양한 함량비로 함유하는 제형예 4-11의 화장료, 으름덩굴 추출물 대신 정제수를 함유한 비교제형예 4의 화장료 및 으름덩굴 추출물 대신에 방부제로 메칠파라벤과 이미다졸리디닐우레탄을 함유하는 비교제형예 5의 화장료를 제조하였다.In order to examine the antimicrobial effect of the vinegar extract, Comparative Example 4 (Comparative Example 4) containing purified water in place of the cosmetic material of Formulation Example 4-11, Crude Vine Extract, which contained the crude Crane Extract of Preparation Example 3 in various contents ratios, Of the cosmetic composition of Comparative Example 5 containing methylparaben and imidazolidinyl urethane as preservatives instead of the cosmetic and milky vine extracts of Comparative Example 5 were prepared.
성분
ingredient
(제조예 3)Vine Extract
(Production Example 3)
상기 표 6의 제형예 및 비교제형예의 화장료를 이용하여 박테리아 및 곰팡이에 대한 방부 효과를 측정하였다.The cosmetic effects of the formulation examples and comparative formulations of Table 6 were used to measure the preservative effect against bacteria and fungi.
먼저, 박테리아의 경우 상기 제형예 4-6의 화장료 및 비교제형예 4, 5의 화장료 20-30 g에 대장균(Escherichia coli ; ATCC 8739), 슈도모나스 애루지노사(Pseudomonas aeruginosa ; ATCC9027) 및 스타필로코쿠스 아우레우스(Staphylococcus aureus ; ATCC6538)의 혼합 균액을 시료당 초기 농도가 107 cfu/g 되도록 첨가 혼합하였다. 이들을 30-32℃ 항온조에서 4주간 배양하면서 1, 7, 14, 21 및 28일 간격으로 각 화장료를 1 g씩 취하여 생균수를 측정하였다. 측정결과는 하기의 표 7에 나타내었다.First, in the case of bacteria, 20 to 30 g of the cosmetic of Formulation Example 4-6 and Comparative Formulation Examples 4 and 5 were mixed with 20 g of Escherichia coli ; ATCC 8739), Pseudomonas aeruginosa (ATCC 9027) and Staphylococcus aureus (ATCC 6538) were added and mixed at an initial concentration of 10 7 cfu / g per sample. 1 g of each cosmetic was taken at 1, 7, 14, 21 and 28 days intervals while culturing them in a thermostat at 30-32 ° C for 4 weeks, and the number of viable cells was measured. The measurement results are shown in Table 7 below.
다음으로 곰팡이의 경우에는, 칸디다 알비칸스(Candida albicans ; ATCC10231), 페니실리움 씨트리눔(Penicillium citrinum ; KCTC2123) 및 아스퍼질러스 나이거(Aspergillus niger ; ATCC16404)의 혼합균액을 시료당 107cfu/g이 되도록 첨가 혼합한 후 25℃ 항온조에서 배양하면서 7일 간격으로 변취 유무와 시료표면의 균사 및 포자발생 유무를 관찰하여, 그 결과를 하기의 표 7에 나타내었다.Next, in the case of mold, Candida albicans ( Candida albicans ; ATCC 10231), Penicillium citrinum ; KCTC2123) and Aspergillus niger (ATCC16404) were added at a concentration of 10 7 cfu / g per sample and cultured at 25 ° C in a thermostatic bath at intervals of 7 days, And the results are shown in Table 7 below.
- : 8주간 변취 및 균사와 포자 발생이 없고 양호-: No spawning and mycelium spawning for 8 weeks and good
+ :４주 이내에 기벽이나 뚜껑에 곰팡이 발생+: Molding on the wall or lid within 4 weeks
++ :４주 이내에 변취 및 표면 일부에 곰팡이 발생++: mending within 4 weeks and mold on part of the surface
+++ : 4주 이내에 변취 및 표면 전체에 곰팡이 발생
+++: Mildew and mold on the entire surface within 4 weeks
상기 표 7에서 보는 바와 같이, 방부제를 사용하지 않은 비교예 4의 화장료 조성물은 4주 이내에 변취 및 표면 전체에 곰팡이가 발생하고, 1일만 지나도 박테리아 균이 현저하게 증가하는 것을 알 수 있다. 그러나, 본 발명의 으름덩굴 추출물을 함유하는 제형예 4 내지 제형예 6의 화장료 조성물은 박테리아 및 곰팡이에 대해 농도-의존적으로 항균효과를 나타내었으며, 약 28일이 경과한 후에는 2.0%(w/v)의 함량으로 사용했을 때 방부제인 메칠파라벤과 이미다졸리디닐우레아를 혼합한 비교제형예 5와 유사하거나 더 우수한 방부력이 확보되었고, 배양일 전체로 판단했을 때에도 2.0% 이상의 함량으로 사용했을 때 방부제인 메칠파라벤과 이미다졸리디닐우레아를 혼합한 비교제형예 5에 비해 훨씬 우수한 방부력이 확보됨을 알 수 있었다.
As shown in Table 7, the cosmetic composition of Comparative Example 4, which did not use the preservative, showed molds on the surface and the entire surface within 4 weeks, and the bacterial counts were remarkably increased even after 1 day. However, the cosmetic compositions of Formulation Examples 4 to 6 containing the extract of the present invention showed antimicrobial effects on bacteria and fungi in a concentration-dependent manner, and after about 28 days, 2.0% (w / v), a repellency similar to or better than Comparative Formulation Example 5 in which methylparaben, which is a preservative, and imidazolidinyl urea were mixed, was obtained, and when it was judged based on the whole culture day, it was used in an amount of 2.0% or more It was found that a far superior buoyancy was obtained as compared to Comparative Formulation Example 5 in which the preservative methylparaben and imidazolidinyl urea were mixed.
실험예Experimental Example 6. 으름덩굴 추출물의 피부 주름 개선효과 6. Skin wrinkle improvement effect of mulberry extract
본 발명의 으름덩굴 추출물을 함유하는 화장료의 피부 주름 개선효과에 대한 임상실험을 실시하였다. 임상시험은 각 화장료의 실제 사용 테스트를 통하여 평가하였다.Clinical trials were carried out on the effect of improving the skin wrinkles of the cosmetic compositions containing the extract of Crane vine of the present invention. Clinical trials were conducted through actual use tests of each cosmetic product.
즉, 임상실험은 제조예 1의 으름덩굴 추출물을 함유하고 있는 제형예 1와 으름덩굴 추출물 대신에 아데노신 3%(v/v)로 대체한 크림 화장료 조성물을 사람을 대상으로 화장료의 사용으로 인한 피부 주름 개선 효과를 확인 및 비교 40명의 여성을 대상으로 실험군을 각각 20명씩으로 나누어 으름덩굴 추출물 대신에 아데노신 3%(v/v)로 대체한 크림(비교 제형예 6, 표 7에는 함량을 표기하지 않음) 처리군, 으름덩굴 추출물을 포함하는 제형예 2의 실험군의 두 그룹으로 나누고, 얼굴 양쪽면을 사용하여 8주 후의 주름 개선 효과를 육안으로 평가하여 주름 개선 정도를 확인하였다. 이 평가를 토대한 주름 개선 효과 결과는 하기의 표 13에 나타내었다.That is, the clinical test was conducted in the same manner as in Preparation Example 1, except that Formulation Example 1, which contained Crane Extract of Preparation Example 1, and Crème cosmetic composition which was replaced with adenosine 3% (v / v) instead of Crane Extract, Confirmation and Comparison of Wrinkle Reduction Effects Creams were prepared by substituting adenosine 3% (v / v) for adrenocyte extract instead of 20% for each experimental group in 40 women (Comparative Formulation Example 6, Treated group, and the control group of Formulation Example 2, which contained an extract of Aspergillus oryzae. The wrinkle improvement effect was visually evaluated after 8 weeks using both sides of the face, and the degree of wrinkle improvement was confirmed. The results of the wrinkle-improving effect based on this evaluation are shown in Table 13 below.
실험 완료 후 피부 주름 개선 효과는 제품 사용 전과 8주 사용 후의 각 피검자의 주름 개선 효과를 숙련된 의사의 육안 관찰 및 기기측정(Replica & Skin visiometer, C+K Electronic Co., Germany)을 통하여 평가하였으며, 으름덩굴 추출물을 포함하는 화장료 조성물의 주름 개선 효과 (육안 평가 및 기기평가)의 실험 결과는 하기의 표 8에 나타낸 바와 같다.The wrinkle improvement effect of each subject before and 8 weeks after the completion of the experiment was evaluated by a skilled physician's naked eye and instrument measurement (Replica & Skin visiometer, C + K Electronic Co., Germany) The results of the wrinkle-improving effect (visual evaluation and device evaluation) of the cosmetic composition containing the extract of Vinegar are shown in Table 8 below.
(주름깊이)Device Rating
(Wrinkle depth)
(%)Improvement rate
(%)
(%)Effective rate
(%)
(으름덩굴 추출물)Formulation Example 1
(Vine extract)
(아데노신)Comparative Formulation Example 2
(Adenosine)
상기 표 8의 결과에서도 알 수 있듯이, 으름덩굴 추출물 대신 주름 개선 효과가 있는 것으로 알려진 아데노신을 함유하는 비교 제형예 2의 화장료와 유사한 결과가 나타나, 으름덩굴 추출물의 우수한 주름 개선 효과를 나타냄을 알 수 있었다. 또한 본 발명의 으름덩굴 추출물을 함유하는 화장료를 피부에 도포한 대부분의 피검자들에게서 피부 자극을 관찰할 수 없었다.As can be seen from the results of Table 8, similar results were obtained with the cosmetic preparation of Comparative Formulation Example 2 containing adenosine, which is known to have a wrinkle-reducing effect instead of the vinegar extract, showing excellent wrinkle-reducing effect of the vinegar extract there was. In addition, skin irritation could not be observed in most of the subjects who applied the cosmetic composition containing the extract of Vinegar of the present invention to the skin.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120139605A KR20140071716A (en) | 2012-12-04 | 2012-12-04 | Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120139605A KR20140071716A (en) | 2012-12-04 | 2012-12-04 | Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140071716A true KR20140071716A (en) | 2014-06-12 |
Family
ID=51125966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120139605A Ceased KR20140071716A (en) | 2012-12-04 | 2012-12-04 | Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20140071716A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102382002B1 (en) * | 2021-10-22 | 2022-04-01 | (주)바이오신펩 | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex and natural ingredients |
| KR102462080B1 (en) * | 2022-03-31 | 2022-11-03 | (주)바이오코스텍 | Cosmetic compositions containing fermented extracts of herb mixture |
| KR20250099473A (en) | 2023-12-22 | 2025-07-02 | 주식회사 코스메카코리아 | Cosmetic composition for improving skin itching comprising the complex extract of sophora japonica fruits, dried ginger and akebiae quinata caulis, and manufacturing method thereof |
-
2012
- 2012-12-04 KR KR1020120139605A patent/KR20140071716A/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102382002B1 (en) * | 2021-10-22 | 2022-04-01 | (주)바이오신펩 | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex and natural ingredients |
| KR102462080B1 (en) * | 2022-03-31 | 2022-11-03 | (주)바이오코스텍 | Cosmetic compositions containing fermented extracts of herb mixture |
| KR20250099473A (en) | 2023-12-22 | 2025-07-02 | 주식회사 코스메카코리아 | Cosmetic composition for improving skin itching comprising the complex extract of sophora japonica fruits, dried ginger and akebiae quinata caulis, and manufacturing method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101885195B1 (en) | Cosmetic Composition with Fermentative Extract of Osmanthus fragrans | |
| KR20160123732A (en) | Cosmetic composition comprising the extract of cynara scolymus and brassica oleracea var. botrytis as active ingredient | |
| KR101716428B1 (en) | Cosmetic composition containing fermentative extract of hippocampus coronatus as active ingredient | |
| KR101176528B1 (en) | Cosmetic composition comprising the extract of salvia plebeia as active ingredient | |
| KR101445642B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR101817129B1 (en) | Cosmetic Composition Comprising Extracts of Pinecone of Pinus sylvestris | |
| KR20170076147A (en) | Composition for improving skin | |
| KR101176526B1 (en) | Cosmetic Composition Comprising the extract of Spiraea prunifolia var.simpliciflora as Active Ingredient | |
| KR20150101810A (en) | Fermentative Extract of Hippophae rhamnoides with Increased Amount of Vitamin C Fermented by Aureobasidium pullulans and Cosmetic Composition containing the same | |
| KR101323068B1 (en) | Cosmetic composition comprising the extract of Viburnum odoratissimum var. awabuki as active ingredient | |
| KR20140071716A (en) | Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent | |
| KR101479245B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR101775485B1 (en) | Cosmetic composition containing fermentative extract of Spatholobus suberectus Dunn as active ingredient | |
| KR20190030397A (en) | Cosmetic Composition Comprising Extracts of Pinecone of Pinus sylvestris | |
| KR101618180B1 (en) | Cosmetic composition comprising an extract of the tissue-cultured raoulia australis shoot | |
| KR20190048935A (en) | Cosmetic composition comprising extract of red onion fermented by aureobasidium pullulans | |
| KR101176525B1 (en) | Cosmetic Composition Comprising Acer tegmentosum Maxim as Active Ingredient | |
| KR101479244B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR101664878B1 (en) | Cosmetic composition containing fractions of allium hookeri as active ingredient | |
| KR101996547B1 (en) | Cosmetic composition with skin whitening effect containing diphylleia grayi extract | |
| KR20140071713A (en) | Cosmetic composition comprising the extract of Metaplexis japonica as active ingredient | |
| KR20120002870A (en) | Cosmetic composition containing calcium tree extract having whitening and anti-aging effect | |
| KR20150045010A (en) | Cosmetic composition comprising the extract of Allium hookeri as active ingredient | |
| KR20160004593A (en) | Cosmetic Composition Comprising Extract of Pittosporum tobira as Active Ingredient | |
| KR20130026678A (en) | Cosmetic composition comprising the extract of lastrea japonica as active ingredient and cosmetic method therreof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20121204 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140926 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150120 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20150413 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150120 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20140926 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |